Kadmon Corporation, LLC clinical trials

Acquired by Sanofi, Nov 9, 2021 · source ↗

The registry lists 34 studies whose lead sponsor is Kadmon Corporation, LLC. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 12, 2026.

• 34studies on the registry
• 0open to participants now

Studies

Recruiting first, then most recently updated. Showing 34 of 34. All Sanofi studies →

• Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic TherapyWithdrawnNCT05567406Phase 2

  Sponsor listed in the registry: Kadmon, a Sanofi Company · First submitted after Kadmon became part of Sanofi

• A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male SubjectsCompletedNCT05806567Phase 1

  Sponsor listed in the registry: Kadmon, a Sanofi Company · First submitted after Kadmon became part of Sanofi

• A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid TumorsTerminatedNCT04242147Phase 1

  Sponsor listed in the registry: Kadmon, a Sanofi Company · First submitted before Kadmon became part of Sanofi

• Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213CompletedNCT05305989Phase 2

  Sponsor listed in the registry: Kadmon, a Sanofi Company · First submitted after Kadmon became part of Sanofi

• Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic TherapyTerminatedNCT03640481Phase 2

  Sponsor listed in the registry: Kadmon, a Sanofi Company · First submitted before Kadmon became part of Sanofi

• KD025 in Subjects With Diffuse Cutaneous Systemic SclerosisTerminatedNCT03919799Phase 2

  Sponsor listed in the registry: Kadmon, a Sanofi Company · First submitted before Kadmon became part of Sanofi

• A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host DiseaseCompletedNCT02841995Phase 2

  Sponsor listed in the registry: Kadmon, a Sanofi Company · First submitted before Kadmon became part of Sanofi

• A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male SubjectsCompletedNCT05918627Phase 1

  Sponsor listed in the registry: Kadmon, a Sanofi Company · First submitted after Kadmon became part of Sanofi

• A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female SubjectsCompletedNCT05918614Phase 1

  Sponsor listed in the registry: Kadmon, a Sanofi Company · First submitted after Kadmon became part of Sanofi

• A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female SubjectsCompletedNCT05918588Phase 1

  Sponsor listed in the registry: Kadmon, a Sanofi Company · First submitted after Kadmon became part of Sanofi

• Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic SclerosisTerminatedNCT04680975Phase 2

  Sponsor listed in the registry: Kadmon, a Sanofi Company · First submitted before Kadmon became part of Sanofi

• Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKDCompletedNCT03203642Phase 2

  Sponsor listed in the registry: Kadmon, a Sanofi Company · First submitted before Kadmon became part of Sanofi

• A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT01559363Phase 1/2

  Sponsor listed in the registry: Kadmon, a Sanofi Company · First submitted before Kadmon became part of Sanofi

• A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary FibrosisCompletedNCT02688647Phase 2

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic ImpairmentCompletedNCT04166942Phase 1

  Sponsor listed in the registry: Kadmon, a Sanofi Company · First submitted before Kadmon became part of Sanofi

• Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025CompletedNCT03907540Phase 1

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line TherapyCompletedNCT02317627Phase 2

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• Bioavailability of Belumosudil (KD025) in Healthy Male SubjectsCompletedNCT02557139Phase 1

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy VolunteersCompletedNCT03530995Phase 1

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101TerminatedNCT02616055Phase 2

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line ChemotherapyTerminatedNCT01487174Phase 3

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• Study of XL647 in Subjects With Non-Small-Cell Lung CancerCompletedNCT00364780Phase 2

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• Study of XL647 Administered Orally Daily to Patients With Solid TumorsCompletedNCT00336765Phase 1

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid TumorsCompletedNCT00086528Phase 1

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or ErlotinibCompletedNCT00522145Phase 2

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)CompletedNCT03096080Phase 1

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative BioavailabilityCompletedNCT04735822Early Phase 1

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast CancerTerminatedNCT02154529Phase 1/2

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis VulgarisCompletedNCT02106195Phase 2

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque PsoriasisCompletedNCT02852967Phase 2

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal MetastasesCompletedNCT02616393Phase 2

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• Study of Tesevatinib Monotherapy in Patients With Recurrent GlioblastomaCompletedNCT02844439Phase 2

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep CWithdrawnNCT00951223

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi

• Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and RibavirinTerminatedNCT00456248Phase 4

  Sponsor listed in the registry: Kadmon Corporation, LLC · First submitted before Kadmon Corporation, LLC became part of Sanofi